Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Innovations in Preeclampsia
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Innovations in Preeclampsia

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: 22 December 2025 | Viewed by 3481

Special Issue Editors

Dr. Jeffrey M. Denney

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Section for Maternal-Fetal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
Interests: preterm birth; fetal growth restriction; preeclampsia; multiple gestation; prenatal diagnosis
Dr. Liliya Yamaleyeva

E-Mail Website
Guest Editor
Department of Surgery, Section on Hypertension and Vascular Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
Interests: preeclampsia; fetal growth restriction; renin-angiotensin system
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Simply stated, preeclampsia is new-onset hypertension with proteinuria during gestation. However, preeclampsia is complex, virtually affects every organ, and is often confused with other entities (e.g., exacerbation of chronic hypertension). Recent advances in diagnostic tools (e.g., FDA-approved analyte assays), understanding of preeclampsia, and new evidence regarding maternal care deserve communication in a Special Issue format.

Aim and scope of the Issue: Our aim is to provide clinicians and scientists with a forum to communicate recent advances in the understanding of the pathophysiology, diagnosis, care, and prevention of preeclampsia. Submissions will be reviewed to tie in insights with numerous portals and pathophysiologic processes that lead to pre-eclampsia, hypertensive disorders of pregnancy, and imitators of preeclampsia (e.g., acute fatty liver, HELLP, TTP-HUS, SLE exacerbation). The scope of targeted papers includes contributions adding to the understanding, care, and prevention of preeclampsia as well as imitators of preeclampsia.

Dr. Jeffrey M. Denney
Dr. Liliya Yamaleyeva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • preeclampsia
  • pathophysiology
  • renin
  • SFlt-1
  • PlGF
  • hypertensive disorders of pregnancy
  • imitators of preeclampsia
  • vascular reactivity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

24 pages, 1430 KiB  
Review
Current Approaches and Innovations in Managing Preeclampsia: Highlighting Maternal Health Disparities
by Alexis G. Dickerson, Christiana A. Joseph and Khosrow Kashfi
J. Clin. Med. 2025, 14(4), 1190; https://doi.org/10.3390/jcm14041190 - 11 Feb 2025
Viewed by 2360
Abstract
Preeclampsia (PE) is a major cause of maternal mortality and morbidity, affecting 3–6% of pregnancies worldwide and ranking among the top six causes of maternal deaths in the U.S. PE typically develops after 20 weeks of gestation and is characterized by new-onset hypertension [...] Read more.
Preeclampsia (PE) is a major cause of maternal mortality and morbidity, affecting 3–6% of pregnancies worldwide and ranking among the top six causes of maternal deaths in the U.S. PE typically develops after 20 weeks of gestation and is characterized by new-onset hypertension and/or end-organ dysfunction, with or without proteinuria. Current management strategies for PE emphasize early diagnosis, blood pressure control, and timely delivery. For prevention, low-dose aspirin (81 mg/day) is recommended for high-risk women between 12 and 28 weeks of gestation. Magnesium sulfate is also advised to prevent seizures in preeclamptic women at risk of eclampsia. Emerging management approaches include antiangiogenic therapies, hypoxia-inducible factor suppression, statins, and supplementation with CoQ10, nitric oxide, and hydrogen sulfide donors. Black women are at particularly high risk for PE, potentially due to higher rates of hypertension and cholesterol, compounded by healthcare disparities and possible genetic factors, such as the APOL1 gene. This review explores current and emerging strategies for managing PE and addresses the underlying causes of health disparities, offering potential solutions to improve outcomes. Full article
(This article belongs to the Special Issue Innovations in Preeclampsia)
►▼ Show Figures

Figure 1

Other

Jump to: Review

24 pages, 2889 KiB  
Systematic Review
Hypertensive Disorders of Pregnancy and Peripartum Cardiomyopathy: A Meta-Analysis of Prevalence and Impact on Left Ventricular Function and Mortality
by Aleksandar Biljic-Erski, Nina Rajovic, Vedrana Pavlovic, Zoran Bukumiric, Aleksandar Rakic, Marija Rovcanin, Jelena Stulic, Radomir Anicic, Jovana Kocic, Jelena Cumic, Ksenija Markovic, Dimitrije Zdravkovic, Dejana Stanisavljevic, Srdjan Masic, Natasa Milic and Dejan Dimitrijevic
J. Clin. Med. 2025, 14(5), 1721; https://doi.org/10.3390/jcm14051721 - 4 Mar 2025
Viewed by 795
Abstract
Background: The purpose of this meta-analysis was to examine the prevalence of hypertensive disorders of pregnancy (HDPs), particularly preeclampsia (PE), in peripartum cardiomyopathy (PPCM)-affected pregnancies, and to evaluate whether a HDP significantly alters the prognosis of PPCM, with specific reference to the recovery [...] Read more.
Background: The purpose of this meta-analysis was to examine the prevalence of hypertensive disorders of pregnancy (HDPs), particularly preeclampsia (PE), in peripartum cardiomyopathy (PPCM)-affected pregnancies, and to evaluate whether a HDP significantly alters the prognosis of PPCM, with specific reference to the recovery of left ventricular function (LVEF) and mortality. Methods: A total of 5468 potentially eligible studies were identified, and 104 were included in the meta-analysis. For pooling proportions, the inverse variance methods with logit transformation were used. Complete recovery of LVEF (>50%) and mortality were expressed by odds ratios (ORs), with 95% confidence intervals (CIs). The Peto OR (POR) was used in cases of rare events. Baseline LV function and baseline LV end-diastolic diameter (LVEDD) were summarized by the mean difference (MD) and 95% confidence interval (CI). Results: The summary estimate of the prevalence of HDPs and PE in women with PPCM was 36% and 25%, respectively. Patients with HDPs and, more specifically, PE with PPCM had a higher chance of complete recovery (OR = 1.87; 95%CI = 1.64 to 2.13; p < 0.001 and OR = 1.98; 95%CI 1.69 to 2.32; p < 0.001, respectively), a higher baseline LVEF (MD, 1.42; 95% CI 0.16 to 2.67; p = 0.03 and MD, 1.69; 95% CI 0.21 to 3.18; p = 0.03, respectively), and a smaller baseline LVEDD (MD, −1.31; 95% CI −2.50 to −0.13; p = 0.03 and MD, −2.63; 95% CI −3.75 to −1.51; p < 0.001, respectively). These results, however, did not translate into a significant difference in 12-month mortality (POR = 0.80; 95% CI = 0.57 to 1.13; p = 0.21 and POR = 1.56; 95% CI 0.90 to 2.73; p = 0.12, respectively). Conclusions: The findings of this study may contribute to evidence that can be utilized to aid in the risk stratification of patients with PPCM regarding their long-term prognoses. Full article
(This article belongs to the Special Issue Innovations in Preeclampsia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop